Abstract
Report description
The Bigpharma Agreements Handbook 2007 provides comprehensive and
unprecedented access to the partnering agreements entered into by the worlds
leading fifty biopharma companies.
Understanding the flexibility of a prospective partner's negiotated deals
terms provides critical insight into the negotiation process in termsof what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 1,000 links to online copies of actual contract
documents as submitted to the Securities Exchange Commission by bigpharma and
their partners.
Contract documents provide the answers to numerous questions about a
prospective partners flexibility on a wide range of important issues, many of
which will have a significant impact on each parties ability to derive value
from the deal.
The initial chapters of this report provide an orientation of bigpharma's
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 lists the top 50 leading biopharma companies based on
2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in
2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes
the top deals of 2005-6 according to reported deal size.
The main body of the report is provided in chapter 5. Each of the top 50
bigpharma companies is provided with a brief summary followed by a
comprehensive listing of contract documents available in the public domain.
The listing is sorted by deal type - therefore co-promotion deals are listed
separately to licensing, M&A and supply deals, and so on.
Each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand. In
addition, the contract document collection can be used offline and is
available on CD-Rom.
Key benefits
Bigpharma Agreements Handbook 2007 provides the user with the following key benefits:
- Comprehensive access to over 1,000 actual contracts entered into by the
leading fifty biopharma companies*
- Insight into the terms included in a partnering agreement, together with
real world clause examples
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report scope
Bigpharma Agreements Handbook 2007 is intended to provide the reader
with an in-depth understanding of the partnering activities and interests of
the leading fifty biopharma companies worldwide, enabling the effective
assessment and selection of partners of choice, based on the latest knowledge
of a company's approach to partnering.
Bigpharma Agreements Handbook 2007 includes:
- The tools to enable effective and efficient preparation for partnering
negotiation with bigpharma
- Detailed partnering activity and interests profiles for the leading fifty
bigpharma companies
- Listing of over 1,000 contract documents between bigpharma and partner
companies
- The leading M&A and partnering deals by value 2005-6
- Most active M&A and partnering dealmakers 2005-6
- The leading partnering resources
For each company in Bigpharma Agreements Handbook 2007, the available
contracts are listed by deal type, including:
- Co-development
- Co-marketing
- Co-promotion
- Collaborative R&D
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply
Each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand. In
addition, the contract document collection can be used offline and is
available on CD-Rom.
The Bigpharma Agreements Handbook 2007 provides comprehensive access to
available contract documents for each of the fifty bigpharma companies.
Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Number of pages:
The report is comprised of 310 pages.
| 
View Cart
